<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03903549</url>
  </required_header>
  <id_info>
    <org_study_id>JH-181698</org_study_id>
    <nct_id>NCT03903549</nct_id>
  </id_info>
  <brief_title>Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers</brief_title>
  <official_title>A Positron Emission Tomography (PET) Study to Investigate [18F]D6-FP-DTBZ ([18F]P17-059) for Potential Use as a Radioligand for Vesicular Monoamine Transporter (VMAT2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Five Eleven Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Five Eleven Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the initial safety profile of [18F]P17-059 in healthy volunteers&#xD;
      including dosimetry determination, and compares regional brain uptake and kinetics of&#xD;
      [18F]P17-059 in Parkinson's disease patients with regional brain uptake and kinetics of&#xD;
      [18F]P17-059 in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regional brain uptake of [18F]P17-057 in Parkinson patients compared healthy volunteers</measure>
    <time_frame>0 - 90 minutes post injection</time_frame>
    <description>Quantitative estimates of [18F]P17-059 uptake in brain - SUV and non-displaceable Binding Potential</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative organ [18F]P17-059 activity for estimates of radiation absorbed dose and effective dose</measure>
    <time_frame>0 - 240 minutes post injection</time_frame>
    <description>Dosimetry</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Brain uptake and kinetics in Parkinson patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Brain uptake and kinetics in healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosimetry in healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]P17-059</intervention_name>
    <description>Injection of &lt; 10 mCi [18F]P17-059 followed by PET/CT scanning</description>
    <arm_group_label>Brain uptake and kinetics in Parkinson patients</arm_group_label>
    <arm_group_label>Brain uptake and kinetics in healthy volunteers</arm_group_label>
    <arm_group_label>Dosimetry in healthy volunteers</arm_group_label>
    <other_name>[18F]D6FP</other_name>
    <other_name>[18F]D6FPDTBZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion criteria (Healthy Volunteers)&#xD;
&#xD;
               1. Healthy non-smoking males and females, as determined by medical history, physical&#xD;
                  examination, vital signs, clinical laboratory tests, and an electrocardiogram.&#xD;
&#xD;
                  1.1 Male subjects and their child bearing potential partners must be willing to&#xD;
                  use a reliable method of birth control for the duration of the study.&#xD;
&#xD;
                  1.2 Female subjects who are of childbearing potential must agree to use an&#xD;
                  adequate method of contraception for the duration of the study.&#xD;
&#xD;
               2. Between 45-85 years old, inclusive.&#xD;
&#xD;
               3. BMI between 18-32 kg/m2 inclusive.&#xD;
&#xD;
               4. Have clinical laboratory test results within the reference ranges for the&#xD;
                  population or results within acceptable deviations that are not considered by the&#xD;
                  investigator to be clinically significant.&#xD;
&#xD;
               5. All subjects and their partners of childbearing potential must commit to use two&#xD;
                  methods of contraception, one of which must be a barrier method, from the time of&#xD;
                  screening and throughout the study and until follow-up.&#xD;
&#xD;
               6. Less than 195 cm (6 feet and 5 inches) tall in order to accommodate the whole&#xD;
                  body scanning.&#xD;
&#xD;
               7. Have sufficient venous access.&#xD;
&#xD;
               8. Willing to give written informed consent and to comply with the study&#xD;
                  restrictions.&#xD;
&#xD;
          -  Inclusion criteria (PD patients)&#xD;
&#xD;
               1. Signed and dated written informed consent.&#xD;
&#xD;
               2. Male or Female.&#xD;
&#xD;
               3. Age 45-90.&#xD;
&#xD;
               4. Diagnosis of clinically established idiopathic PD consistent with the Movement&#xD;
                  Disorder Society Clinical Diagnostic Criteria for Parkinson's disease (PD)&#xD;
                  (Postuma, et al., 2014).&#xD;
&#xD;
               5. BMI between 18-32 kg/m2 inclusive.&#xD;
&#xD;
               6. Have clinical laboratory test results within the reference ranges for the&#xD;
                  population or results within acceptable deviations that are not considered by the&#xD;
                  investigator to be clinically significant.&#xD;
&#xD;
               7. All subjects and their partners of childbearing potential must commit to use two&#xD;
                  methods of contraception, one of which must be a barrier method, from the time of&#xD;
                  screening and throughout the study and until follow-up.&#xD;
&#xD;
               8. Less than 195 cm (6 feet and 5 inches) tall in order to accommodate the whole&#xD;
                  body scanning.&#xD;
&#xD;
               9. Have sufficient venous access.&#xD;
&#xD;
              10. Absence of an established clinical movement disorder diagnosis other than&#xD;
                  Parkinson's disease.&#xD;
&#xD;
              11. Symptoms mild in intensity, this includes Hoehn &amp; Yahr ≤ 2 (Exceptions are&#xD;
                  allowed for subjects who meet criteria for Hoehn &amp; Yahr stage 2/5 due to early&#xD;
                  onset of postural instability and/or gait impairment out of proportion to his/her&#xD;
                  other Parkinson signs and symptoms);&#xD;
&#xD;
              12. Montreal Cognitive Assessment (MoCA) score ≥ 22;&#xD;
&#xD;
              13. Can tolerate imaging visit procedures&#xD;
&#xD;
              14. Willing to give written informed consent and to comply with the study&#xD;
                  restrictions.&#xD;
&#xD;
              15. Female patients must have had her last natural menstruation at least ≥24 months&#xD;
                  prior to the Screening Visit or have been surgically sterilized prior to the&#xD;
                  Screening Visit. Male patients must use two methods of contraception in&#xD;
                  combination if his female partner is of childbearing potential; OR have been&#xD;
                  surgically sterilized prior to the Screening Visit.&#xD;
&#xD;
              16. In the opinion of the investigator based on medical history and physical&#xD;
                  examination, can safely tolerate tracer administration and the scanning&#xD;
                  procedures.&#xD;
&#xD;
          -  exclusion criteria (Healthy volunteers)&#xD;
&#xD;
               1. Are currently enrolled in or discontinued within the last 30 days from a clinical&#xD;
                  trial involving an investigational drug or device (other than the study drug) or&#xD;
                  are currently enrolled in any other type of medical research.&#xD;
&#xD;
               2. Are currently experiencing neuropsychiatric illness or severe systemic disease&#xD;
                  based on history and physical exam.&#xD;
&#xD;
               3. Have participated in other research protocols in the last year such that&#xD;
                  radiation exposure would exceed the annual limits.&#xD;
&#xD;
               4. Pregnant or nursing women.&#xD;
&#xD;
               5. History of head trauma with prolonged loss of consciousness (&gt;10 minutes) or any&#xD;
                  neurological condition including stroke or seizure (excluding childhood febrile&#xD;
                  seizure).&#xD;
&#xD;
               6. History or presence of any clinically relevant hematological, hepatic,&#xD;
                  respiratory, cardiovascular, renal, metabolic, endocrine, or CNS disease or other&#xD;
                  medical conditions that are not well controlled, may put the subject at risk,&#xD;
                  could interfere with the objectives of the study, or make the subject unsuitable&#xD;
                  for participation in the study for any other reason in the opinion of the&#xD;
                  principal investigator.&#xD;
&#xD;
               7. Suffer from claustrophobia and would be unable to undergo MRI and PET scanning.&#xD;
&#xD;
               8. Any confirmed significant allergic reactions against any drug, or multiple&#xD;
                  allergies.&#xD;
&#xD;
               9. Currently uses prescription medications, over-the-counter drugs or herbal&#xD;
                  remedies such as St. Johns Wort) which cannot be discontinued 14 days (or &lt; 5&#xD;
                  half-lives, whichever is longer), prior to the PET scan and throughout the study.&#xD;
                  Exceptions include daily multiple vitamins.&#xD;
&#xD;
          -  exclusion criteria (PD patients)&#xD;
&#xD;
               1. Have a known CNS structural lesion such as stroke or tumor that likely accounts&#xD;
                  for their symptoms;&#xD;
&#xD;
               2. Have current clinically significant cardiovascular disease or clinically&#xD;
                  important abnormalities on screening ECG (including but not limited to QTc &gt; 450&#xD;
                  msec);&#xD;
&#xD;
               3. Are currently taking medications that are known to cause QT-prolongation;&#xD;
&#xD;
               4. Are currently taking medications with narrow therapeutic windows (e.g. warfarin&#xD;
                  or other anticoagulant therapies);&#xD;
&#xD;
               5. Are currently taking tetrabenazine (TBZ), valbenazine (Ingrezza), amphetamine&#xD;
                  type drugs;&#xD;
&#xD;
               6. Has taken tetrabenazine (TBZ) in the preceding 3 months;&#xD;
&#xD;
               7. Have a current clinically significant endocrine or metabolic disease, pulmonary,&#xD;
                  renal or hepatic impairment, or cancer (excluding localized basal cell carcinoma&#xD;
                  and in situ prostate cancer) that would interfere with completion of the study;&#xD;
&#xD;
               8. Have a recent history (within the past year) of alcohol or substance abuse or&#xD;
                  dependence;&#xD;
&#xD;
               9. Are females of childbearing potential who are not surgically sterile, not&#xD;
                  refraining from sexual activity or not using reliable contraception. Females must&#xD;
                  not be pregnant (negative serum beta-hCG at the time of screening and negative&#xD;
                  urine beta-hCG on the day of imaging), must not be breastfeeding at screening,&#xD;
                  must avoid becoming pregnant and use adequate contraceptive methods for 14 days&#xD;
                  prior to and 24 hours after administration of 18F-D6-FPDTBZ for injection;&#xD;
&#xD;
              10. Have had prior intracranial surgery; and&#xD;
&#xD;
              11. Are receiving any investigational medications, or have participated in a trial&#xD;
                  with investigational medications within the last 30 days.&#xD;
&#xD;
              12. Contraindications of MRI. Incidental findings on MRI scans that are pathognomonic&#xD;
                  for an active disease or pathological process which requires medical intervention&#xD;
                  will be exclusionary.&#xD;
&#xD;
              13. History of, or suffers from, claustrophobia or feels that he or she will be&#xD;
                  unable to lie still on their back in the MRI or PET scanner.&#xD;
&#xD;
              14. Urinary toxicology positive for nonprescribed substances&#xD;
&#xD;
              15. Previous allergic reaction to the radiotracer ([18F]D6-FP-DTBZ) or substances of&#xD;
                  similar chemical structure or excipients.&#xD;
&#xD;
              16. Diagnosis of secondary parkinsonism caused by a brain tumor, cranial trauma, or&#xD;
                  metabolic diseases (diabetes mellitus, hepatic insufficiency, alcoholism)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins Medical Institutions</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

